Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis

Arthritis Rheum. 1988 Apr;31(4):465-70. doi: 10.1002/art.1780310402.


In a series of 111 patients with Wegener's granulomatosis who were given cyclophosphamide therapy, hemorrhagic cystitis, diagnosed on the basis of gross hematuria or at cystoscopy (or both), developed in 17 (15%). Most of these patients recovered uneventfully, with or without the discontinuation of cyclophosphamide, but 4 patients suffered a significant loss of blood, and bladder carcinoma developed in 3. New microhematuria also occurred in 52 patients (47%). The dose and duration of cyclophosphamide were greater in the group that had urotoxicity. Long-term followup of patients with hemorrhagic cystitis is mandatory for the detection of late recurrences or the development of bladder malignancy. New therapies are being directed at protecting the bladder from urotoxicity during cyclophosphamide treatment.

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Child
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects*
  • Cyclophosphamide / therapeutic use
  • Cystitis / chemically induced*
  • Cystitis / complications
  • Cystitis / therapy
  • Female
  • Granulomatosis with Polyangiitis / drug therapy*
  • Hematuria / etiology
  • Hemorrhage / chemically induced*
  • Hemorrhage / therapy
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Urinary Bladder / drug effects


  • Cyclophosphamide